AIM: To evaluate the efficacy and safety of intravitreal injection of Conbercept as the treatment of choroidal neovascularization due to high myopia.

METHODS: The study was a retrospective analytical case series. We reviewed medical records of 15 patients(16 eyes)with choroidal neovascularization second to high myopia that had enrolled in our hospital from January 2013 to December 2016. All patients have received one or more conbercept injections based on medical condition and observed the best corrected visual acuity(BCVA)and macular retinal thickness before and after the last injection. The duration of the last follow-up was from 1.5mo to 28mo.

RESULTS: Totally 15 patients(16 eyes)were enrolled in this study. All patients received conbercept injections. Among all the patients, 6 eyes were given one treatment, 7 eyes were given two treatments and 3 eyes three treatments. Before retreatment, the mean intraocular pressure was 16.44±1.39mmHg before treatment, and the average intraocular pressure was 16.75±1.41mmHg after the last treatment. The difference was not statistically significant(P>0.05). BCVA was 1.14±0.35 before treatment, BCVA was 0.71±0.21 at the last follow-up. The difference was statistically significant(P<0.05). The thickness of the macular retina was 361.63±33.59μm before treatment, and it was 287.25±30.31μm at the last follow-up, and the difference was statistically significant(P<0.05). And there was no case of endophthalmitis, stroke, and retinal detachment during follow-up.

CONCLUSION: Intravitreal injection of conbercept can effectively improve the patient's BCVA in the short term and reduce the macular fovea retinal thickness. No significant adverse events are observed.